WilmerHale represented Volastra Therapeutics, a clinical stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), in closing its $60 million Series A financing, which was led by founding investors Polaris Partners and ARCH Venture Partners alongside Eli Lilly and Company. Also participating were Droia Ventures, Catalio Capital Management, Vida Ventures, Cornell University, and Meyers Ventures LLC, an affiliate of Ocean Road Advisors.  Volastra Therapeutics also concurrently completed an in-license of Amgen’s sovilnesib (AMG650), an oral, first-in-class small molecule inhibitor of KIF18A.

The WilmerHale legal team representing Volastra Therapeutics for the Series A financing was led by Cynthia Mazareas and included Hilary Baker-Jennings, Sam Rothberg, Alex Bloom and Cynthia Sullivan.